Type 2 Diabetes: Causes, Symptoms, Diagnosis, and Evidence-Based Treatment

What Is Type 2 Diabetes?

Type 2 diabetes is a chronic metabolic disorder defined by high blood glucose resulting from defective insulin signaling. The pancreas still produces insulin, but cells in muscle, fat, and liver tissue resist its effects. Over time, beta cells compensate by secreting more insulin until they can no longer keep pace with demand.

The condition develops gradually, often over years, and many people carry it without knowing. The Centers for Disease Control and Prevention (CDC) estimates that 8.7 million American adults have undiagnosed diabetes. Unlike type 1 diabetes, which results from autoimmune destruction of beta cells and typically presents in childhood, type 2 diabetes emerges from a combination of genetic predisposition and metabolic stress. The distinction matters because treatment strategies differ sharply. Type 1 always requires exogenous insulin. Type 2 often responds to oral medications, injectable GLP-1 receptor agonists, and weight management before insulin becomes necessary [1].

The economic burden is staggering. The American Diabetes Association reported that diagnosed diabetes cost the U.S. healthcare system $412.9 billion in 2022, including $306.6 billion in direct medical costs [2].

How Insulin Resistance Drives Type 2 Diabetes

Insulin resistance is the root defect. It begins years before glucose levels cross the diagnostic threshold.

When insulin binds to cell-surface receptors, it triggers a signaling cascade that allows glucose transporters (GLUT4) to move to the cell membrane and pull glucose inside. In insulin resistance, this signaling pathway becomes impaired. The pancreas responds by producing more insulin, a state called hyperinsulinemia, which can keep blood glucose within normal range for years [3]. The problem is that chronically elevated insulin drives fat storage, promotes inflammation, and accelerates cardiovascular damage even while fasting glucose looks acceptable on routine labs.

Visceral adipose tissue is a primary driver. Fat cells in the abdominal cavity release free fatty acids and inflammatory cytokines (TNF-alpha, IL-6) that directly interfere with insulin receptor signaling in the liver and skeletal muscle [4]. This explains why waist circumference is a stronger predictor of type 2 diabetes risk than BMI alone. A prospective cohort study published in The Lancet found that each 10 cm increase in waist circumference raised diabetes risk by 34% in men and 36% in women, independent of BMI [5].

Genetic factors also play a role. Having one parent with type 2 diabetes raises lifetime risk to roughly 40%; having two parents with the condition pushes it above 70%.

Prediabetes: The Warning Window

Prediabetes represents the metabolic state between normal glucose regulation and overt diabetes. The American Diabetes Association (ADA) defines it as fasting plasma glucose of 100-125 mg/dL, 2-hour oral glucose tolerance test value of 140-199 mg/dL, or HbA1c of 5.7-6.4% [6].

An estimated 97.6 million American adults (38% of the adult population) have prediabetes. Without intervention, 15-30% will progress to type 2 diabetes within five years.

The Diabetes Prevention Program (DPP), a landmark NIH-funded trial enrolling 3,234 participants, showed that structured lifestyle intervention (150 minutes per week of moderate exercise plus 7% body weight loss) reduced progression to type 2 diabetes by 58% over 2.8 years. Metformin reduced it by 31% [7]. The 15-year follow-up of this trial confirmed that lifestyle intervention delayed diabetes onset by an average of 4 years, while metformin delayed it by 2 years [8].

This is the most responsive phase for treatment. Glucose patterns are still partially reversible. Beta cell function, once lost, does not fully recover.

Symptoms and Diagnosis

Many people with early type 2 diabetes experience no symptoms at all. That silence is what makes screening protocols critical.

When symptoms do appear, the classic presentation includes increased thirst (polydipsia), frequent urination (polyuria), unexplained weight loss, blurred vision, slow-healing wounds, and fatigue. These signals indicate that blood glucose has been elevated long enough to affect kidney filtration, lens osmolality, and cellular energy supply.

The ADA's 2024 Standards of Care recommend screening all adults starting at age 35 using any of three tests [9]:

• Fasting plasma glucose (FPG): 126 mg/dL or higher on two occasions
• HbA1c: 6.5% or above, reflecting average glucose over the preceding 2-3 months
• 2-hour oral glucose tolerance test (OGTT): 200 mg/dL or higher

For individuals who are overweight (BMI of 25 or above) and have one or more additional risk factors (family history, physical inactivity, history of gestational diabetes, polycystic ovary syndrome, or membership in a high-risk ethnic group), screening should begin earlier than age 35. Gestational diabetes, which affects approximately 2-10% of pregnancies in the United States each year, significantly raises the mother's risk: women with a history of gestational diabetes face a 50% probability of developing type 2 diabetes within 5-10 years postpartum [10].

First-Line and Second-Line Medications

Metformin remains the global first-line drug. It works by reducing hepatic glucose output and improving peripheral insulin sensitivity without causing hypoglycemia or weight gain.

The UK Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced diabetes-related death by 42% and all-cause mortality by 36% in overweight patients with type 2 diabetes compared to conventional dietary management alone [11]. Starting dose is typically 500 mg once or twice daily, titrated to a maximum of 2,000-2,550 mg per day. Gastrointestinal side effects (nausea, diarrhea, abdominal discomfort) affect roughly 20-30% of patients but often resolve with extended-release formulations.

When metformin alone does not achieve an HbA1c target below 7%, the ADA recommends adding a second agent based on the patient's clinical profile:

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) have become a preferred add-on, especially for patients with established cardiovascular disease or obesity. In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events (MACE) by 26% over 2.1 years versus placebo in patients with type 2 diabetes at high cardiovascular risk [12]. Tirzepatide, a dual GIP/GLP-1 receptor agonist, reduced HbA1c by up to 2.07% from a baseline of 8.28% in the SURPASS-1 trial (N=478) at its highest dose [13].

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower glucose by blocking renal glucose reabsorption, producing an estimated 60-80 grams of urinary glucose excretion per day. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease [14]. These agents also slow progression of diabetic kidney disease, making them a strong choice for patients with an estimated glomerular filtration rate (eGFR) between 20-60 mL/min/1.73 m².

Sulfonylureas (glipizide, glimepiride) are older, inexpensive agents that stimulate insulin secretion. They remain widely prescribed globally but carry risks of hypoglycemia and weight gain that newer drug classes avoid.

Insulin therapy becomes necessary when beta cell function declines to the point where oral and injectable non-insulin agents cannot maintain glycemic targets. About 27.8% of adults with diagnosed diabetes use insulin, either alone or in combination with other medications [15].

Lifestyle Interventions That Move the Numbers

Diet and exercise are not accessories to pharmacotherapy. They are the foundation.

The DiRECT trial (N=306), published in The Lancet, showed that among participants who lost 15 kg or more through a structured low-calorie diet program, 86% achieved diabetes remission at 12 months, defined as HbA1c below 6.5% without diabetes medications [16]. Even moderate weight loss of 5-10% produced remission in a significant proportion of participants.

Dr. Roy Taylor, who led the DiRECT trial, stated: "Type 2 diabetes is a simple condition of too much fat within the liver and pancreas. If this excess fat is removed, the condition reverses."

Specific dietary patterns with evidence for glycemic benefit include the Mediterranean diet, which reduced the incidence of type 2 diabetes by 52% in the PREDIMED trial (N=3,541) among high-cardiovascular-risk adults supplementing with extra-virgin olive oil compared to a control diet [17]. The ADA does not endorse a single dietary pattern but recommends reducing refined carbohydrates, increasing fiber intake to 25-30 g per day, and limiting added sugars.

For physical activity, the ADA recommends at least 150 minutes per week of moderate-to-vigorous aerobic activity (brisk walking, cycling, swimming), plus 2-3 sessions per week of resistance training [18]. Resistance exercise independently improves insulin sensitivity by increasing glucose uptake in skeletal muscle, which accounts for roughly 80% of postprandial glucose disposal.

Complications: What Sustained Hyperglycemia Does

Uncontrolled type 2 diabetes damages both small and large blood vessels systematically.

Microvascular complications include diabetic retinopathy (the leading cause of new blindness in adults aged 20-74), diabetic nephropathy (diabetes is the number one cause of end-stage kidney disease, accounting for approximately 38% of new cases annually), and peripheral neuropathy, which affects up to 50% of people with diabetes and is the primary driver of non-traumatic lower-limb amputations [19].

Macrovascular complications include coronary artery disease, stroke, and peripheral arterial disease. A meta-analysis published in JAMA covering 450,000 participants found that each 1% increase in HbA1c was associated with an 18% increase in cardiovascular events [20].

The UKPDS demonstrated that every 1% reduction in HbA1c was associated with a 37% reduction in microvascular complications, a 21% reduction in diabetes-related deaths, and a 14% reduction in myocardial infarction [21].

These numbers argue for aggressive, early glycemic control. The ADA sets a general HbA1c target below 7% for most adults, with more stringent goals (below 6.5%) for younger patients with short disease duration and less stringent targets (below 8%) for older adults with multiple comorbidities.

Monitoring and Long-Term Management

Ongoing monitoring involves more than checking blood glucose periodically.

The ADA recommends HbA1c testing at least twice per year for patients meeting treatment targets and quarterly for those whose therapy has changed or who are not meeting goals [9]. Continuous glucose monitoring (CGM) devices, once reserved for type 1 diabetes, are increasingly prescribed for type 2 patients on insulin or those struggling with glycemic variability. CGM data provides time-in-range metrics (target: 70-180 mg/dL for more than 70% of the day) that correlate with HbA1c but offer real-time feedback that traditional finger-stick testing cannot.

Annual screening should include dilated eye exams, urine albumin-to-creatinine ratio (to detect early nephropathy), comprehensive foot exams, lipid panels, and blood pressure measurement. The ADA recommends statin therapy for virtually all adults with diabetes aged 40-75 and an LDL-C target below 100 mg/dL, or below 70 mg/dL for those with established atherosclerotic cardiovascular disease [9].

As Dr. Robert Ratner, former Chief Scientific and Medical Officer of the ADA, stated: "The goal isn't just to lower blood sugar. It's to prevent the complications that steal quality of life and shorten lifespan."

Blood pressure control is equally important. The ADA recommends a target below 130/80 mmHg, with ACE inhibitors or ARBs preferred for patients with albuminuria because of their renoprotective effects [9].

Patients diagnosed with type 2 diabetes should have HbA1c measured within three months of initiating or adjusting therapy, with a target reduction of at least 0.5% at that interval to confirm the treatment plan is working.